Effects of nebivolol on vascular endothelial and myocardial function in diabetes mellitus

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 1, 2011, Pages 56-64

  Doggen, Kris ^a   Fransen, Paul ^a   Lemmens, Katrien ^a   De Keulenaer, Gilles W ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

adrenergic receptor antagonist; diabetes mellitus; endothelium; myocardium; nebivolol; nitric oxide

Indexed keywords

BISOPROLOL; NEBIVOLOL; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; FEMALE; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE RELAXATION; HEART PAPILLARY MUSCLE; HEART RIGHT VENTRICLE; IN VIVO STUDY; MALE; MOUSE; MUSCLE TWITCH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BENZOPYRANS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; FEMALE; MALE; MICE; MICE, TRANSGENIC; NITRIC OXIDE; ORGAN CULTURE TECHNIQUES; PAPILLARY MUSCLES; RANDOM ALLOCATION; VASODILATION;

EID: 79960420665     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31821c4974     Document Type: Article

References (41)

1. López-Sendón JBC, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25: 1341-1362.
2. Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54:1491-1499.
3. Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795-3801. (Pubitemid 43739521)
4. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
5. Dawes M, Brett SE, Chowienczyk PJ, et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999;48:460-463. (Pubitemid 29417735)
6. Lekakis JP, Protogerou A, Papamichael C, et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther. 2005;19:277-281. (Pubitemid 41778808)
7. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511-514. (Pubitemid 32738117)
8. Cosentino F, Bonetti S, Rehorik R, et al. Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1-selective receptor blockade. J Hypertens. 2002;20:421-428. (Pubitemid 34913741)
9. Guerrero EI, Ardanaz N, Sevilla MA, et al. Cardiovascular effects of nebivolol in spontaneously hypertensive rats persist after treatment withdrawal. J Hypertens. 2006;24:151-158. (Pubitemid 41818100)
10. Guerrero E, Voces F, Ardanaz N, et al. Long-term treatment with nebivolol improves arterial reactivity and reduces ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2003;42: 348-355. (Pubitemid 37071690)
11. Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006;48:677-684. (Pubitemid 44843872)
12. Georgescu A, Popov D, Dragan E, et al. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension. Eur J Pharmacol. 2007;570:149-158. (Pubitemid 47247683)
13. Mason RP, Kubant R, Jacob RF, et al. Loss of arterial and renal nitric oxide bioavailability in hypertensive rats with diabetes: effect of beta-blockers. Am J Hypertens. 2009;22:1160-1166.
14. Mollnau H, Schulz E, Daiber A, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol. 2003;23: 615-621. (Pubitemid 36438074)
15. Baumhäkel M, Schlimmer N, Büyükafsar K, et al. Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein e-knockout mice. J Pharmacol Exp Ther. 2008;325: 818-823. (Pubitemid 351728031)
16. Maffei A, Di Pardo A, Carangi R, et al. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension. 2007;50:652-656. (Pubitemid 47442727)
17. Rozec B, Erfanian M, Laurent K, et al. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol. 2009;53:1532-1538.
18. Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res. 1999;43:595-606. (Pubitemid 29369258)
19. Rozec B, Quang TT, Noireaud J, et al. Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta. Br J Pharmacol. 2006;147:699-706.
20. de Groot AA, Mathy M, van Zwieten PA, et al. Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J Cardiovasc Pharmacol. 2003;42:232-236. (Pubitemid 36899676)
21. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005;112:1198-1205. (Pubitemid 41216127)
22. Troost R, Schwedhelm E, Rojczyk S, et al. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol. 2000;50: 377-379.
23. Cominacini L, Fratta Pasini A, Garbin U, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol. 2003;42:1838-1844. (Pubitemid 37433667)
24. de Groot AA, Mathy M, van Zwieten PA, et al. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol. 2004;43:148-153. (Pubitemid 38032077)
25. Fratta Pasini A, Garbin U, Nava MC, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005;23:589-596. (Pubitemid 40684718)
26. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001;22:36-52. (Pubitemid 32187802)
27. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29-34.
28. Marwick TH. Diabetic heart disease. Heart. 2006;92:296-300.
29. Brutsaert DL, Meulemans AL, Sipido KR, et al. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ Res. 1988;62:358-366. (Pubitemid 18041957)
30. Jones SP, Girod WG, Granger DN, et al. Reperfusion injury is not affected by blockade of P-selectin in the diabetic mouse heart. Am J Physiol Heart Circ Physiol. 1999;277:H763-H769. (Pubitemid 29415992)
31. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000; 14:439-447. (Pubitemid 30143162)
32. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol. 2003;284:F1138-F1144. (Pubitemid 36578440)
33. Mohan P, Brutsaert DL, Paulus WJ, et al. Myocardial contractile response to nitric oxide and cGMP. Circulation. 1996;93:1223-1229. (Pubitemid 26087026)
34. Bluhm WF, Kranias EG, Dillmann WH, et al. Phospholamban: a major determinant of the cardiac force-frequency relationship. Am J Physiol Heart Circ Physiol. 2000;278:H249-H255. (Pubitemid 30101877)
35. Li L, Desantiago J, Chu G, et al. Phosphorylation of phospholamban and troponin I in beta-adrenergic-induced acceleration of cardiac relaxation. Am J Physiol Heart Circ Physiol. 2000;278: H769-H779. (Pubitemid 30152533)
36. Kogler H, Soergel DG, Murphy AM, et al. Maintained contractile reserve in a transgenic mouse model of myocardial stunning. Am J Physiol Heart Circ Physiol. 2001;280:H2623-H2630.
37. Tong CW, Gaffin RD, Zawieja DC, et al. Roles of phosphorylation of myosin binding protein-C and troponin I in mouse cardiac muscle twitch dynamics. J Physiol. 2004;558:927-941. (Pubitemid 39199113)
38. Gao WD, Perez NG, Marban E. Calcium cycling and contractile activation in intact mouse cardiac muscle. J Physiol. 1998;507:175-184. (Pubitemid 28102684)
39. Widén C, Barclay CJ. Resting metabolism of mouse papillary muscle. Pflugers Arch. 2005;450:209-216. (Pubitemid 40966574)
40. Brutsaert DL, Sys SU. Relaxation and diastole of the heart. Physiol Rev. 1989;69:1228-1315. (Pubitemid 19255838)
41. Mebazaa A, De Keulenaer GW, Paqueron X, et al. Activation of cardiac endothelium as a compensatory component in endotoxin-induced cardiomyopathy: role of endothelin, prostaglandins, and nitric oxide. Circulation. 2001;104:3137-3144. (Pubitemid 34014071)